PharmaTher Holdings Ltd.
PHRRF · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.84 | -0.74 | 0.00 | 6.24 |
| FCF Yield | -0.66% | -2.63% | -1.44% | -1.48% |
| EV / EBITDA | -78.47 | -20.05 | -47.34 | -57.34 |
| Quality | ||||
| ROIC | -42.76% | -54.13% | -29.31% | -20.45% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.53 | 0.74 | 0.71 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 43.82% | -15.59% | 17.05% | 5.03% |
| Safety | ||||
| Net Debt / EBITDA | 2.16 | 1.75 | 3.43 | 4.29 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |